Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reported his stock holdings as of 11/26/2024. He directly holds 3,461 shares of common stock and indirectly holds 69,600 shares. The indirect holdings are noted with a footnote for further details. The total amount of shares beneficially owned by Huntsman is 73,061. This report provides insight into the CEO's stake in the company, which may interest investors monitoring executive stock ownership. The transaction status is completed, and the report does not indicate any recent buying or selling activity by Huntsman. Investors may consider this information when evaluating the company's leadership commitment and potential future performance.

Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reported his stock holdings as of 11/26/2024. He directly holds 3,461 shares of common stock and indirectly holds 69,600 shares. The indirect holdings are noted with a footnote for further details. The total amount of shares beneficially owned by Huntsman is 73,061. This report provides insight into the CEO's stake in the company, which may interest investors monitoring executive stock ownership. The transaction status is completed, and the report does not indicate any recent buying or selling activity by Huntsman. Investors may consider this information when evaluating the company's leadership commitment and potential future performance.